Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)

NCT04046224 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
36
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sangamo Therapeutics